Citius Oncology nearing commercial launch of LYMPHIR for CTCL in H2 2025

CITIUS ONCOLOGY, INC.

Commercial-scale manufacturing completed; inventory sufficient for 12-18 months post-launch with 60-month shelf life.
70 institutional oncology centers already registered via the LYMPHIR website.
LYMPHIR included in NCCN guidelines; assigned permanent J-code for reimbursement.
Parent Citius Pharma's recent capital raise supports final launch preparations.
Strategic partnership discussions underway with financial advisor to expand market reach.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.